[Federal Register: May 31, 2002 (Volume 67, Number 105)]
[Notices]
[Page 38133]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr31my02-105]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, DHHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by agencies of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Enhanced Distribution of Therapeutic Agents After Local Delivery
Krys Bankiewicz et al. (NINDS)
U.S.P.A. Nos. 60/250,286 filed 30 Nov 2000 and 60/286,308 filed 25
Apr 2001
Licensing Contact: Norbert Pontzer; 301/496-7736 ext. 284; e-mail:
np59n@nih.gov
Many experimental therapies will rely on the local parenchymal
delivery of macromolecules or nucleic acids for their success. However,
the volume of distribution of many of these potential therapeutic
agents is restricted by their interactions with the extracellular
matrix and cellular receptors. Heparin-sulfate proteoglycans are a cell
surface component which bind to many different types of molecules such
as growth factors, cytokines and chemokines and viruses such as
cytomegalovirus, herpes simplex virus and HIV.
These inventions provide a method of dramatically increasing the
volume of distribution and effectiveness of certain therapeutic agents
after local delivery by the use of facilitating agents as described in
Neuroreport. 2001 Jul 3;12(9):1961-4 entitled ``Convection-enhanced
delivery of AAV-2 combined with heparin increases TK gene transfer in
the rat brain'' and in Exp Neurol. 2001 Mar;168(1):155-61 entitled
``Heparin coinfusion during convection-enhanced delivery (CED)
increases the distribution of the glial-derived neurotrophic factor
(GDNF) ligand family in rat striatum and enhances the pharmacological
activity of neurturin.'' These methods are especially useful when used
in conjunction with technology described and claimed in U.S. Patent
5,720,720 entitled ``Convection-enhanced drug delivery.'' Licenses for
methods to enhance the distribution of all claimed therapeutics except
adeno-associated viral vectors are available.
Sol Fusin: Use of GP64-6HIS to Catalyze Membrane Fusion
D. H. Kingsley and J. J. Zimmerberg (NICHD)
DHHS Reference Nos. E-113-99/0 filed 18 Feb 1999 and E-113-99/1
filed 15 Nov 2001
Licensing Contact: Pradeep Ghosh; 301/496-7736 ext. 211; e-mail
ghoshp@od.nih.gov
An efficient drug delivery system is a necessity for a wide range
of therapeutic interventions. This technology pertains to a process
related to the solubilizing of insoluble membrane proteins, thus
generating soluble and functional version (sol-proteins) of previously
insoluble proteins. Specifically, the invention relates to the addition
of histidine amino acids to the cytoplasmic domains of membrane and
viral envelope proteins for the purpose of solubilizing, purifying and/
or reconstituting functional viral envelope proteins in lipid-
containing vesicles. The modified protein mediates fusion of the
resulting vesicular membrane with other lipid membranes, thus creating
an efficient delivery system. The proteins in this form have been
referred to as ``sol-fusin'' and the resultant sol-fusin/liposome
complex is potentially able to catalyze delivery of therapeutic,
genetic, or antigenic compounds both in vivo and in vitro. Thus,
pharmaceutical and vaccine manufacturers may use these proteoliposomes
as tools to deliver active therapeutic, genetic or antigenic agents
without destruction by lysosomes. In addition to being useful as a
delivery tool, the sol-fusin/ liposomes can be used to mimic viral
infections. The triggering of sol-fusin is low pH-dependent, and thus
may perhaps facilitate oral ingestion and gastrointestinal absorption
of the bioactive agents because of their direct membrane fusion
mediating activity.
Dated: May 23, 2002.
Jack Spiegel,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. 02-13731 Filed 5-30-02; 8:45 am]
BILLING CODE 4140-01-P